• Explore /
  • Poster
  • / Development and application of a precision cell-free DNA (cfDNA) minimal residual disease (MRD) test to enable optimized treatment selection in patients with genitourinary (GU) cancers.

Development and application of a precision cell-free DNA (cfDNA) minimal residual disease (MRD) test to enable optimized treatment selection in patients with genitourinary (GU) cancers.

Abstract Poster

Authors

null

Derrian Cooley

University of Michigan, Ann Arbor, MI

Derrian Cooley , Ulka N. Vaishampayan , Samuel Kaffenberger , Linda Drnek , Bryan Johnson , Laura Elaine Lamb , Nickolay A. Khazanov , Daniel H. Hovelson , Kat Kwiatkowski , Daniel R. Rhodes , Scott A. Tomlins , Khaled Hafez , Lindsey A. Herrel , Jeffrey S. Montgomery , Amy Gursky , Aaron M. Udager , Todd Matthew Morgan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT05082701

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 473)

DOI

10.1200/JCO.2024.42.4_suppl.473

Abstract #

473

Poster Bd #

K14

Abstract Disclosures

Similar Posters

First Author: De-Zhen Guo

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Minimal residual disease assessment in colorectal cancer (MiRDA-C).

Minimal residual disease assessment in colorectal cancer (MiRDA-C).

First Author: Arvind Dasari

First Author: Yinyin Chang

First Author: Michael Mitchell